Highlights from the CHMP September 2026 Meeting are out! 📢 At the Sep'26 CHMP meeting, nine positive opinions related to oncology were reported. Here are the main highlights: 1) Cisplatin is no longer the gatekeeper in bladder cancer. 👉 The CHMP dropped the cisplatin-ineligibility restriction for Keytruda + Padcev in resectable muscle-invasive bladder cancer 2) The label race has moved upstream. 👉 All five oncology extensions took a therapy into an earlier setting or a wid

Highlights from the CHMP July 2026 Meeting are out! Six oncology calls came out of the July CHMP meeting. Below are the key takeaways: 1) ADCs own the front line. 👉 Enhertu and Trodelvy both cleared first-line metastatic breast settings in combination. 2) Breast cancer is where the density is. 👉 All three positive opinions are in the Breast Cancer space 3) A met endpoint is not an EU approval. 👉 POTOMAC succeeded, and the FDA approved. CHMP still questioned the benefit-ris